David Colpman
David Colpman is a senior member of Shire’s Business Development team focused on building the global speciality business through licensing and M&A.
During the last eleven years at Shire, David has completed around 10 licensing deals. In addition he has run numerous M&A, product divestment and acquisition projects. Specific achievements include in-licensing the GI product Lialda/Mezavant with sales potential of over $400M, leading the teams that bought Transkaryotic Therapies for $1.6BN, Movetis for $550M and in 2007 divesting a business to Almirall for $213M.
David acts as advisor to the Venture Group, Sunstone Capital and was formerly a member of the board of Ace BioSciences.
Prior to joining Shire he led GlaxoWellcome’s UK Business Development team and prior to that he was Head of Licensing and Alliances at Novo Nordisk in Denmark. David is a pharmacist by training, he spent part of his early career working in Japan and has a basic command of the Japanese language.
or